Adjuvant treatment with tamoxifenBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7055.493c (Published 24 August 1996) Cite this as: BMJ 1996;313:493
Care is necessary
- R D Bulbrook, Former head
- clinical endocrinology laboratory, Imperial Cancer Research Fund Clachan, Dunlichity, Inverness IV1 2AN
EDITOR,—Michael Baum and Jack Cuzick1 object to my comments about a clinical announcement by the National Cancer Institute that a trial comparing five years of adjuvant treatment with tamoxifen for breast cancer with a longer period of such treatment has been stopped.2 They say that the announcement is a “dubious and previously discredited process” (why?) and is based on unpublished data. Table 1 gives the data, which are available under the American Freedom of Information Act.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial